Dr. Marek Tyl

Dr. Marek Tyl currently serves as the Business Development Manager for Europe within Eppendorf's Corporate Development team, overseeing strategy, venture capital investments, and mergers and acquisitions. He joined Eppendorf's Corporate Venture Capital arm in September 2023.​

Prior to this, Dr. Tyl was a Scientific Advisor and Innovation Hub Lead at Takeda Pharmaceuticals in London, where he was involved in innovation scouting incl. digital health solutions.  Before his tenure at Takeda, he founded and led the Global Innovation Forum, a global network and startup accelerator connecting innovative companies, entrepreneurs, investors, researchers, and policymakers across multiple innovation clusters in Europe, Asia, and North America. Additionally, as Founder and Managing Director of Cambridge Squared, a UK-based boutique consulting firm, he specialized in sourcing and due diligence of investment opportunities in therapeutics and medical devices for leading multinational pharmaceutical clients.​



Marek earned his Ph.D. in Biochemistry from the University of Cambridge, focusing on structural aspects of chromatin assembly under the supervision of Professor Ernest Laue. Following this, he completed a Postdoctoral Fellowship at Imperial College London, working on the biochemical characterization of novel chromatin-associated factors and their role in cancer.